Let our experts advance your preclinical cancer drug program.
The Noble Life Sciences team has extensive experience in all facets of
oncology drug development. With an intimate understanding of tumor
pathways, drug targets, cell lines, xenograft models and biomarkers, we can
work with you to determine the right experiments to advance your oncology
program.

In Development! PDMX Mouse Models
Virtually all cancer drug development testing is based on activity in primary
tumors whereas metastasis, not the primary tumor, is cause of death in over
90% of cancer cases. For this reason, our goal is to create patient-derived
metastasis mouse (PDMX) models thereby establishing mouse avatars for
preclinical testing of human metastatic tumors. Noble Life Sciences recently
received a Maryland TEDCO Award for Development of ex vivo and in vivo
assays for anti-Metastatic drug development using patented technology, called
Cell Adhesion Matrix-Based (CAM) Enrichment of Invasive CTCs, licensed by
Noble Life Sciences from Vitatex, Inc. to isolate metastasis-initiating circulating
tumor cells (CTCs).

For more information contact us: info@noblelifesci.com

Human Cancer Xenograft Models
Human-mouse xenograft models have been developed using Noble’s cell line
panel, which consists of a diverse collection of cell lines spanning multiple
cancer indications. We also offer orthotopic & ectopic models, metastatic
models, and leukemia models. These models are useful in biomarker
discovery/screening and pathway interrogation and can be used to study the
effect of combination therapies.

Tumor growth delay, tumor growth inhibition, log_{10} cell kill, survival,
combination or adjuvant design approaches may be used to assess your
compound for:
- Drug potency (IC50)
- Apoptosis
- Cell Cycle
- Biomarker Discovery/Screening
- Pathway Interrogation
- Therapeutic Combinations
- Tumor Antigen Testing

About Noble Life Sciences
Noble Life Sciences is a contract research organization (CRO) that provides
integrated in vitro and in vivo preclinical services designed to accelerate drug
development. With deep expertise in drug development, the company offers
access to their top scientists who work collaboratively with researchers to
expedite preclinical and clinical therapeutic development. Our years of
extensive experience together with a focus in oncology, inflammation,
autoimmune, and infectious diseases allow us to bring strong scientific insight
to your discovery programs. For more information:
Visit: www.noblelifesci.com
e-mail: info@noblelifesci.com

Biomarker Discovery & Validation
Noble’s scientists have created a process for selection and
validation of fit-for-purpose biomarkers. Our team of
scientists can develop a biomarker discovery and/or
validation strategy that may include:
- Discovery of RNA or protein-based biomarkers that track
disease or drug activity
- Identification of qualifying biomarkers using our extensive biomarker database and well-
characterized cancer cell lines
- Drug/biomarker pairing and validation studies
- Pharmacodynamic modeling of response biomarkers in animal models for candidate selection,
safety evaluation and patient
dosing strategies
- Evaluation of combination therapies for response in target
pathways
- Biomarker "fit for purpose" validation

Biomarker Selection & Verification with Molecular Tumor Profiling
Noble’s scientific team combines their experiential knowledge of cancer signaling
pathways with public and proprietary genomic data
across a compendium of cell
lines and clinical samples to
identify and validate
biomarkers of drug response.

In Vivo Biomarker Validation
Noble’s expertise in animal
models is used to provide in vivo validation of
pharmacodynamic markers and to characterize on-target
dependencies of the client’s
drug.